ERA-EDTA Symposium 2018

Read story

ESC Congress 2017

Read story

ERA-EDTA Congress 2017

Read story

ESC Congress 2016

Read story

EASD 2016

Read story

European Biopharmaceutical Review

Read story

New York Academy of Science Symposium

Read story

The Complement System: Part 1

Read story

The Complement System: Part 2

Read story

The Complement System: Part 3

Read story

Diabetes Mellitus

Read story

Chronic Kidney Disease

Read story

The New Frontier of Epigenetics

Read story

Readers, Writers & Erasers in Epigenetics

Read story

Clinical Trials Series: Part 1

Read story

Clinical Trials Series: Part 2

Read story

Clinical Trials Series: Part 3

Read story

Pharmacoeconomics

Read story

Sanofi Biogenius Competition CTV News feature

Read story

World Diabetes Day

Read story

ERA-EDTA Congress 2017

On June 5, 2017, Resverlogix supported a symposium at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress in Madrid, Spain: "Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?" 

Symposium Agenda

Introduction - Vincent M Brandenburg, MD, Aachen, Germany.

Kamyar Kalantar-Zadeh, MD – UC Irvine School of Medicine, Irvine, USA. "BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?"

Marta Ruiz-Ortega – Foundación Jiménez Diaz, Madrid, Spain. "Molecular mechanisms involved in the beneficial effect of BET inhibition in experimental renal disease."

Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain. "The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?"

Discussion & Summary - Carmine Zoccali, MD, Reggio Cal, Italy.

Video Presentations & Symposium Highlights can be accessed HERE